Demographics

View past meeting statistics and demographic information for the Annual Meeting.

2017 Registration Numbers

  • Total—39,400
  • Professionals—32,100
  • Exhibitors—5,400
  • Spouse, Guest, Media—1,900
  • Domestic Attendees—53%
  • International Attendees—47%

Top 10 Countries in Attendance in 2017

  • United States—17,168
  • Japan—1,444
  • Germany—1,249
  • France—1,223
  • United Kingdom—1,048
  • China—993
  • Canada—848
  • Brazil—757
  • Switzerland—653
  • Italy—537

Primary Professional Role in 2017

Primary Professional Role Percentage of Attendees Who Responded
Physician 40%
Other 34%
Researcher 9%
Marketing Representative 4%
Business Administrator 3%
Pharmacist 3%
Sales Representative 2%
Biostatistician / Epidemiologist 1%
Student 1%
Office Manager 1%
Nurse 1%
Financial Service Representative 1%

Attendees were allowed to choose only one answer. Responded— 31,200 (97%). No Response—900 (3%). Total—32,100             

Board Certification or International Equivalent in 2017

Board Certification or International Equivalent Percentage of Attendees Who Responded
Medical Oncology 35%
Not Applicable 29%
Internal Medicine 22%
Hematology 14%
Oncology Pharmacy 5%
Other 5%
Laboratory Research 4%
Pharmacology (Clinical) 4%
Surgery (including Surgical Oncology and Surgical Specialties) 3%
Biostatistics / Epidemiology 3%
Radiation Oncology 3%
Gynecologic Oncology 3%
Pediatrics (including Pediatric Oncology and Pediatric Specialties) 2%
Allied Health (e.g. Psychology, Physical Therapy, Social Work, etc.) 2%
Clinical Informatics 2%
Urology / Urologic Oncology 2%
Gastroenterology 2%
Pathology 2%
Oncology Nursing 2%
Health Care Administration 1%
Neurology 1%
Hospice and Palliative Medicine 1%

*Some attendees chose more than one response therefore the total number of responses is greater than the total number of attendees who responded. Responded—20,900 (65%). No Response—11,200 (35%). Totals—32,100 

Primary Interest in 2017

Primary Interest Percentage of Attendees Who Responded
Clinical Trials 38%
Breast Cancer 35%
Lung Cancer 32%
Gastrointestinal (Colorectal Cancer) 21%
Developmental Therapeutics and Translational Research 20%
Tumor Biology 18%
Hematologic Malignancies - Lymphoma and CLL 15%
Gastrointestinal (Noncolorectal Cancer) 13%
Melanoma / Skin Cancers 12%
Hematologic Malignancies - Leukemia, MDS, and Allotransplant 12%
Cancer Prevention, Genetics, and Epidemiology 12%
Genitourinary (Prostate) Cancer 11%
Head and Neck Cancer 10%
Gynecologic Oncology 9%
Genitourinary (Nonprostate) Cancer 8%
Professional Development 7%
Hematologic Malignancies - Plasma Cell Dyscrasia 6%
Health Services Research, Clinical Informatics and Quality of Care 6%
Patient and Survivor Care 6%
Sarcoma  5%
Central Nervous System Tumors 5%
Pediatric Oncology 4%
Care Delivery and Practice Management 4%
Disparities / Access to Care 4%
Other 3%
Ethics 2%
Value 2%
Geriatric Oncology 2%

*Some attendees chose more than one response therefore the total number of responses is greater than the total number of attendees who responded. Responded— 20,350 (63%). No Response—11,750 (37%). Totals—32,100